COLL Collegium Pharmaceutical Inc.
Health Care, filed as COLLEGIUM PHARMACEUTICAL INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab
In 2026 Q2 Third Avenue Management added to Collegium Pharmaceutical.
Who owns this now
Largest portfolio weights among holders, up to 1.1% (Third Avenue Management). Not free-float ownership.
Who owns COLL
Sorted by value, long equity only, as of 2026 Q2.
| History | |||||
|---|---|---|---|---|---|
| Third Avenue Management | Add +17.7% | 182,645 | $6.6M | History |
Insider trades
Open-market buys and sales by COLL's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $2.4M sold by 5 insiders outside a trading plan
- $4.8M sold by 3 insiders under 10b5-1 plans
-
John Gordon Freund DirectorSale$681 20 shares at $34.05 <0.1% of stakeTraded May 18 Filed May 20
-
John Gordon Freund DirectorSale$143K 4,127 shares at $34.54 4.7% of stakeTraded May 15 Filed May 18
-
Nancy Lurker DirectorSale$162K 4,500 shares at $35.97 20% of stakeTraded May 13 Filed May 15
-
Garen G Bohlin DirectorSale$323K 8,700 shares at $37.18 12% of stakeTraded May 11 Filed May 13
-
David Dieter EVP & General CounselPlanned sale$488K 13,976 shares at $34.92 15% of stakeTraded Mar 18 Filed Mar 20
-
David Dieter EVP & General CounselPlanned sale$228K 6,224 shares at $36.65 6.4% of stakeTraded Mar 9 Filed Mar 11
-
Scott Dreyer EVP & Chief Commercial OfficerPlanned sale$2M 49,976 shares at $40.41 41% of stakeTraded Mar 3 Filed Mar 5
-
Scott Dreyer EVP & Chief Commercial OfficerPlanned sale$848K 17,600 shares at $48.17 15% of stakeTraded Dec 8, 2025 Filed Dec 10, 2025
-
Rita J. Balice-Gordon DirectorSale$172K 3,650 shares at $47.03 6.5% of stakeTraded Dec 5, 2025 Filed Dec 9, 2025
-
John A. Fallon DirectorSale$1.6M 34,853 shares at $47.21 35% of stakeTraded Nov 12, 2025 Filed Nov 14, 2025
-
Colleen Tupper CFOPlanned sale$1.2M 30,000 shares at $40.53 19% of stakeTraded Nov 6, 2025 Filed Nov 7, 2025
Also filed in the last 12 months, not counted as buying or selling: 17 stock grants, 10 share withholdings for taxes, and 6 option exercises.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.02 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 2.02,7.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K/A | 9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.01,5.02,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| 8-K | 5.02 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | $537.6M | $482.26M | $691.41M |
| Total non-current assets * | $0.606B | $1.18B | $0.965B |
| Total assets | $1.14B | $1.66B | $1.66B |
| Total current liabilities | $457.92M | $509.51M | $440.03M |
| Total non-current liabilities * | $489.96M | $925.24M | $915.13M |
| Total equity | $195.43M | $228.84M | $301.68M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon